Remarkable new research by a University of Virginia undergraduate may help explain recurrent Crohn’s disease in children and open the door to new ways to treat or even cure the devastating condition.
Bezuclastinib by Cogent Biosciences for Systemic Mastocytosis: Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug